GlassScriptPhysician profile
Jed L Freeman
NPI 1275669038
$1,399.94
in general payments reported to CMS, 2019-2025
20 companies · $408 in 2025
The $408 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $114 · 2021: $342 · 2022: $22.48 · 2023: $203 · 2024: $184 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $779 · Education: $16.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $778.90 |
| Education | $16.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $196.91 | 2023-2025 | Opdivo, Opdualag |
| Incyte Corporation | $165.52 | 2021-2023 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $159.99 | 2019-2025 | Imfinzi |
| Astellas Pharma US INC | $133.43 | 2021-2025 | Vyloy, Xtandi |
| Celgene Corporation | $106.79 | 2023-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $98.79 | 2019-2025 | |
| Genentech USA, INC. | $88.11 | 2019 | |
| Janssen Biotech, INC. | $72.15 | 2021-2025 | Talvey, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $45.30 | 2023-2024 | |
| Eisai INC. | $41.02 | 2021 | |
| Daiichi Sankyo INC. | $40.53 | 2025 | Enhertu, Injectafer |
| Array Biopharma INC | $39.72 | 2025 | Mektovi, Braftovi, Tukysa |
| Genzyme Corporation | $37.65 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $29.86 | 2024 | Onivyde |
| Regeneron Healthcare Solutions, INC. | $29.77 | 2024 | Libtayo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $28.60 | 2023 | |
| Seagen INC. | $25.00 | 2023 | Adcetris |
| Glaxosmithkline, LLC. | $24.17 | 2021 | |
| Octapharma USA, INC. | $21.91 | 2023 | Panzyga |
| Amgen INC. | $14.72 | 2023 | Vectibix, Nplate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jed Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.